These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 37927073)

  • 1. Diagnostic and New Therapeutic Approaches to Two Challenging Pediatric Metabolic Bone Disorders: Hypophosphatasia and X-linked Hypophosphatemic Rickets.
    Aljuraibah F; Alalwan I; Habeb A
    Curr Pediatr Rev; 2024; 20(4):395-404. PubMed ID: 37927073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets.
    Baroncelli GI; Grandone A; Aversa A; Sessa MR; Pelosini C; Michelucci A; Toschi B; Manca M; Isola A; Comberiati P
    Eur J Med Genet; 2024 Aug; 70():104958. PubMed ID: 38950880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare diseases: a challenge in paediatric dentistry.
    Giuca MR
    Eur J Paediatr Dent; 2024 Sep; 25(3):171-171. PubMed ID: 39212455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. X-Linked Hypophosphatemic Rickets: Multisystemic Disorder in Children Requiring Multidisciplinary Management.
    Baroncelli GI; Mora S
    Front Endocrinol (Lausanne); 2021; 12():688309. PubMed ID: 34421819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.
    Laurent MR; De Schepper J; Trouet D; Godefroid N; Boros E; Heinrichs C; Bravenboer B; Velkeniers B; Lammens J; Harvengt P; Cavalier E; Kaux JF; Lombet J; De Waele K; Verroken C; van Hoeck K; Mortier GR; Levtchenko E; Vande Walle J
    Front Endocrinol (Lausanne); 2021; 12():641543. PubMed ID: 33815294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries.
    Al Juraibah F; Al Amiri E; Al Dubayee M; Al Jubeh J; Al Kandari H; Al Sagheir A; Al Shaikh A; Beshyah SA; Deeb A; Habeb A; Mustafa M; Zidan H; Mughal MZ
    Arch Osteoporos; 2021 Mar; 16(1):52. PubMed ID: 33660084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
    Fukumoto S
    J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidisciplinary patient care in X-linked hypophosphatemic rickets: one challenge, many perspectives.
    Raimann A; Mindler GT; Kocijan R; Bekes K; Zwerina J; Haeusler G; Ganger R
    Wien Med Wochenschr; 2020 Apr; 170(5-6):116-123. PubMed ID: 31993875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
    Athonvarangkul D; Insogna KL
    Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders.
    Takashi Y; Kawanami D; Fukumoto S
    Curr Opin Endocrinol Diabetes Obes; 2024 Aug; 31(4):170-175. PubMed ID: 38687287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
    Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
    J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
    Balani S; Perwad F
    Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):531-536. PubMed ID: 32701599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
    Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
    Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatonins: From Discovery to Therapeutics.
    Kritmetapak K; Kumar R
    Endocr Pract; 2023 Jan; 29(1):69-79. PubMed ID: 36210014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperphosphatemia with low FGF7 and normal FGF23 and sFRP4 levels in the circulation characterizes pediatric hypophosphatasia.
    Whyte MP; Zhang F; Wenkert D; Mumm S; Berndt TJ; Kumar R
    Bone; 2020 May; 134():115300. PubMed ID: 32112990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF23 and Associated Disorders of Phosphate Wasting.
    Gohil A; Imel EA
    Pediatr Endocrinol Rev; 2019 Sep; 17(1):17-34. PubMed ID: 31599133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal mineralization: mechanisms and diseases.
    Michigami T
    Ann Pediatr Endocrinol Metab; 2019 Dec; 24(4):213-219. PubMed ID: 31905439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Burosumab for Pediatric X-Linked Hypophosphatemia.
    Imel EA
    Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rickets guidance: part II-management.
    Haffner D; Leifheit-Nestler M; Grund A; Schnabel D
    Pediatr Nephrol; 2022 Oct; 37(10):2289-2302. PubMed ID: 35352187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Therapeutic Agents for Rare Diseases of Calcium and Phosphate Metabolism.
    Roumpou A; Yavropoulou MP; Chronopoulos E; Kassi E
    Horm Metab Res; 2022 Oct; 54(10):645-657. PubMed ID: 36049757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.